The cancers most frequently associated with elevated B12 include: Haematological malignancies: Acute and chronic myeloid leukaemia, polycythaemia vera, and certain lymphomas may increase B12 through abnormal production of B12-binding proteins or release from malignant cells Liver cancers: Hepatocellular carcinoma and metastatic liver disease can cause B12 release from damaged hepatocytes, as the liver stores a majority (approximately 50-60%) of the body's B12 reserves Solid tumours: Various solid organ cancers, particularly those with liver involvement, have been reported in association with elevated B12, though the mechanisms are less well understood The proposed mechanisms linking cancer to elevated B12 include increased production of haptocorrin (a B12-binding protein) by tumour cells, release of B12 from necrotic tumour tissue, and impaired cellular B12 uptake
see MIC Injections for typical timelines and schedules
Reviewed by Jeanine Hattas Wilson This article was reviewed by Jeanine Hattas Wilson
The research seems to underline the potential role AOD 9604 might have in processes connected to the repair of bone, cartilage, and muscle tissues
What is cagrilintide and how does it work Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk
Recalls & Warnings May 24, 2013 Maker of Neuropathic Pain Product Warned For Drug Claims, Misbranding On April 11, 2013, the FDA issued a warning letter to Realm Labs, LLC, following a review of the companys websites which found statements made about its NeuRemedy products to be drug claims
